REQUEST A DEMO
总计
USD $0.00
搜索更多公司

翰森制药集团有限公司 (香港) (中国香港特别行政区)

主营业务: 医药制剂制造
全名: 翰森制药集团有限公司 公司更新日期: 2024.07.27
购买我们的报告为这家公司 USD 29.95 最近财务数据:2023 可有的: 英语 & 中文 下载示例的报告

The Company is a China-based investment holding was incorporated in the Cayman Islands under the Companies Law as an exempted company with limited liability on 2 December 2015. On 14 June 2019, the Company has listed at MAIN Board of Hong Kong Stock Exchange.
The Company and its subsidiaries are principally engaged in the research and development, production and sale of pharmaceutical products in China. The Company's main products include Oulanning, Ameining, Pulaile, Zefei, Xinwei, Xinmei, Zetan, Mailingda, Hengjie, Hengsen, Fulaidi and Ruibote, among others. The Company's products are mainly used for central nervous system disease, oncology, anti-infection, diabetes, digestive tract and cardiovascular treatment. The Company distributes its products in domestic market. The company has over 20 years of R D experience, as evidenced by top-two ranking as of June 30, 2018 in both the number of Category 1.1 innovative drug candidates with IND approval and the number of first-to-market generic drug approvals since 2011. The company has began development of Category 1.1 innovative drugs in 2002. They have become Chinese pharmaceutical companies that have successfully developed and marketed two Category 1.1 innovative drugs with NMEs, including pipeline Category 1.1 innovative drug polyethylene glycol loxenatide, launched in May 2019.
MILESTONES :

1995 - Jiangsu Hansoh as major operating subsidiary was established in China.
2000 - First GMP manufacturing facility in Lianyungang, Jiangsu Province is launched and commenced production of solid oral formulations.
2002 - The company were recognized as a Key High and New-Technology Enterprise of the National Torch Program. The company obtained Chinese GMP certifications for our production of large volume parenteral solutions.
2003 - Active pharmaceutical ingredient, vinorelbine tartrate, was approved by the U.S. FDA.
2006 - The company was received approval to establish a Postdoctoral Program Workstation by the Ministry of Personnel and the National Postdoctoral Management Committee of China.
2008 - The company was certified as a National Enterprise Technology Center.
2014 - Self-developed Category 1.1 innovative drug Mailingda (morinidazole sodium chlorider injection), the latest generation nitroimidazole-class antibiotic, was approved for sale in China.
2015 - core product, Zefei (gemcitabine hydrochloride for injection), was recognized as a Famous China Trademark y the Trademark Office of the State Administration for Industry Commerce of China.
2016 - Hillhouse was brought in as investor. core product, Oulanning (olanzapine tablets), received the China Patent Excellence Award from the State Intellectual Property Office of China. core product, Xinwei (imatinib mesylate tablets), received the first prize for the
Advancement of Science and Technology by the All-China Federation of Industry Commerce. core product, Pulaile (pemetrexed disodium for injection), was approved by the PMDA.

总部
9 Dongjin Road, Economic Technical Development Zone, Lianyungang
连云港; 江苏; 邮编: 222069

联系方式: 购买翰森制药集团有限公司 (香港)报告以查看信息。

网站: http://www.hspharm.com

基本信息
员工总数:
购买翰森制药集团有限公司 (香港)报告以查看信息。
流通股:
购买翰森制药集团有限公司 (香港)报告以查看信息。
注册资本:
购买翰森制药集团有限公司 (香港)报告以查看信息。
财务审计师:
购买翰森制药集团有限公司 (香港)报告以查看信息。
成立日期:
2015
主要管理人员
购买此报告以查看信息。
Chairman
购买此报告以查看信息。
Director/Member of the Board
购买此报告以查看信息。
Director/Member of the Board
购买此报告以查看信息。
Director/Member of the Board
购买此报告以查看信息。
Outside Director
所有权明细
购买此报告以查看信息。
65.73%
购买此报告以查看信息。
16.01%
购买此报告以查看信息。
购买此报告以查看信息。
购买此报告以查看信息。
下属公司
上海翰森生物医药科技有限公司 (中国)
100%
常州恒邦药业有限公司(「常州恒邦」) (中国)
100%
江苏豪森药业集团有限公司 (中国)
100%
公司业绩
图表中的财务价值可在之后获得翰森制药集团有限公司 (香港)报告购买。
寻找的不仅仅是一个公司的报告吗?

EMIS公司简介是一个更大的信息服务的一部分,它结合了公司,行业和国家数据和分析在超过125个新兴市场.

请求EMIS服务的演示
主要财务重点
年增长百分比对于以当地货币近两年CNY。绝对财务数据包含在购买报告中。
销售净额
44.21%
营业收入总计
43.54%
营业利润
138.98%
EBITDA
128.22%
净利润(亏损)
111.47%
总资产
-0.84%
权益总额
15.42%
经营利润率
15.84%
销售收益率
13.33%
股本收益率
4.44%
负债股权比率
-18.61%
速动比率
4.15%
现金比率
1.39%

查看更多信息, 申请试用

购买这家公司报告
需要定期访问公司,行业或国家/地区的信息吗?